CDK4 and neutropenia: Although the incidence of AEs is higher when combining CDK4/6i with endocrine therapy than with endocrine monotherapy, common CDK4/6i-related AEs like neutropenia and leukopenia are well-managed in clinical practice [94], not undermining their first-line treatment status.